Versitol Retard Tablets contain Carbamazepine 200 mg, 300 mg, or 400 mg in a controlled-release formulation. The sustained-release technology provides prolonged drug release, helping to maintain stable plasma concentrations and improve seizure control.

Versitol Retard Tablets provide sustained anticonvulsant activity through controlled drug release, allowing stable plasma drug levels and twice-daily dosing. The formulation is effective in the management of partial and generalized tonic-clonic seizures as well as trigeminal neuralgia, improving therapeutic efficacy and patient compliance.

Versitol Retard Tablets are indicated for the treatment of partial seizures, generalized tonic-clonic seizures, and trigeminal neuralgia.

Carbamazepine exerts its anticonvulsant activity primarily through its active metabolite. It inhibits repetitive high-frequency neuronal firing by blocking voltage-gated sodium channels and prolonging their inactivated state. This stabilizes hyperexcited neuronal membranes, suppresses abnormal electrical discharges, and reduces the spread of seizure activity.

For adults and children over 12 years of age, the recommended starting dose is 200 mg twice daily, with dosage increased by 200 mg/day at weekly intervals until an optimal clinical response is achieved. The dosage generally should not exceed 500 mg twice daily in children 12–15 years, 600 mg twice daily in adolescents 15–18 years, and 800 mg twice daily in adults. In children under 12 years of age, optimal clinical response is generally achieved with daily doses below 35 mg/kg/day, or as directed by the physician.

Versitol Retard Tablets are contraindicated in patients with known hypersensitivity to Carbamazepine or any component of the formulation and in patients with a history of previous bone marrow depression.